Filing Details
- Accession Number:
- 0001079973-24-000701
- Form Type:
- 13D Filing
- Publication Date:
- 2024-05-13 20:00:00
- Filed By:
- Wolf Jeffrey Alan
- Company:
- Scorpius Holdings Inc. (NASDAQ:SCPX)
- Filing Date:
- 2024-05-14
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Jeffrey Wolf | 4,104,922 | 21,256 | 4,104,922 | 21,256 | 10.5% | |
Orion Holdings V | 0 | 11,025 | 0 | 11,025 | Less than 1.0% | |
Seed-One Holdings VI | 0 | 10,231 | 0 | 10,231 | Less than 1.0% | |
Elusys Holdings Inc | 0 | 0 | 0 | 0 | 00.0% |
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 10)*
SCORPIUS
HOLDINGS, INC.
(Name of Issuer)
Common
Stock, Par Value $0.0002 Per Share
(Title of Class of Securities)
42237K
409
(CUSIP Number)
Mr. Jeffrey Wolf
Orion Holdings V, LLC
Seed-One IV, LLC
c/o Scoripus Holdings, Inc.
627 Davis Drive
Morrisville, North Carolina 27560
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
May
13, 2024
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 42237K 409 | 13D | Page 2 of 9 Pages |
(1) | NAME OF REPORTING PERSON | |
Jeffrey Wolf | ||
(2) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ | |
(3) | SEC USE ONLY | |
(4) | SOURCE OF FUNDS
Not applicable | |
(5) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable | |
(6) | CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America | |
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | (7) | SOLE VOTING POWER
4,104,922 |
(8) | SHARED VOTING POWER
21,256 | |
(9) | SOLE DISPOSITIVE POWER
4,104,922 | |
(10) | SHARED DISPOSITIVE POWER
21,256 | |
(11) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
4,126,178 | |
(12) | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ | |
(13) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.5% | |
(14) | TYPE OF REPORTING PERSON
IN |
CUSIP No. 42237K 409 | 13D | Page 3 of 9 Pages |
(1) | NAME OF REPORTING PERSON | |
Orion Holdings V, LLC | ||
(2) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ | |
(3) | SEC USE ONLY | |
(4) | SOURCE OF FUNDS
Not applicable | |
(5) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable | |
(6) | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | (7) | SOLE VOTING POWER
0 |
(8) | SHARED VOTING POWER
11,025 | |
(9) | SOLE DISPOSITIVE POWER
0 | |
(10) | SHARED DISPOSITIVE POWER
11,025 | |
(11) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
11,025 | |
(12) | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ | |
(13) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1.0% | |
(14) | TYPE OF REPORTING PERSON
OO (Limited Liability Company) |
CUSIP No. 42237K 409 | 13D | Page 4 of 9 Pages |
(1) | NAME OF REPORTING PERSON | |
Seed-One Holdings VI, LLC | ||
(2) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ | |
(3) | SEC USE ONLY | |
(4) | SOURCE OF FUNDS
Not applicable | |
(5) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable | |
(6) | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | (7) | SOLE VOTING POWER
0 |
(8) | SHARED VOTING POWER
10,231 | |
(9) | SOLE DISPOSITIVE POWER
0 | |
(10) | SHARED DISPOSITIVE POWER
10,231 | |
(11) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
10,231 | |
(12) | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ | |
(13) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1.0% | |
(14) | TYPE OF REPORTING PERSON
OO (Limited Liability Company) |
CUSIP No. 42237K 409 | 13D | Page 5 of 9 Pages |
(1) | NAME OF REPORTING PERSON | |
Elusys Holdings Inc. | ||
(2) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ | |
(3) | SEC USE ONLY | |
(4) | SOURCE OF FUNDS
Not applicable | |
(5) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐ Not Applicable | |
(6) | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |
NUMBER
OF REPORTING | (7) | SOLE VOTING POWER
0 |
(8) | SHARED VOTING POWER
0 | |
(9) | SOLE DISPOSITIVE POWER
0 | |
(10) | SHARED DISPOSITIVE POWER
0 | |
(11) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
0 | |
(12) | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐ | |
(13) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
00.0% | |
(14) | TYPE OF REPORTING PERSON
CO |
CUSIP No. 42237K 409 | 13D | Page 6 of 9 Pages |
Item 1. | Security and Issuer. |
This Amendment No. 10 (this “Amendment No. 10”) amends the Schedule 13D, dated July 29, 2013 (the “Original 13D”), Amendment No. 1 to the Original 13D, dated February 9, 2017 (“Amendment No. 1”), Amendment No. 2 to the Original 13D, dated March 7, 2017 (“Amendment No. 2”), Amendment No. 3 to the Original 13D, dated April 27, 2017 (“Amendment No. 3”), Amendment No. 4 to the Original 13 D, dated January 2, 2020 (“Amendment No. 4”), Amendment No. 5 to the Original 13D, dated January 4, 2021 (“Amendment No. 5”), Amendment No. 6 to the Original 13D, dated December 13, 2021 (“Amendment No. 6”), Amendment No. 7 to the Original 13D, dated December 30, 2022 (“Amendment No. 7”), Amendment No. 8 to the Original 13D, dated August 21, 2023 (“Amendment No. 8”), and Amendment No. 9, dated December 11, 2023, previously filed by the Reporting Persons (as defined below), as applicable. Mr. Wolf, Orion, Seed-One, and Elusys Holdings Inc. (“Elusys Holdings”) are collectively referred to as the “Reporting Persons.” Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7., Amendment No. 8 or Amendment No. 9. The class of equity securities to which this Amendment No. 10 relates is the Common Stock, of Scorpius Biosciences, Inc., a Delaware corporation (the “Company”). The principal executive offices of the Company are located at 627 Davis Drive, Morrisville, North Carolina 27560 .
Item 3. | Source and Amount of Funds or Other Consideration. |
The information in Item 4 of this Schedule 13D is incorporated herein by reference.
Item 4. | Purpose of Transaction. |
Item 4 is hereby amended and supplemented as follows:
On May 13, 2024, Mr. Wolf indicated to the representative of the underwriters for the Company’s proposed public offering that he was interested in purchasing 2,500,000 Units, each unit consisting of one share of the Company’s common stock and one warrant to acquire one share of the Company’s common stock, upon the same terms as the investors in the proposed offering.
CUSIP No. 42237K 409 | 13D | Page 7 of 9 Pages |
Item 5. | Interest in Securities of the Issuer. |
Item 5 is hereby amended and supplemented as follows.
As of the date hereof, the aggregate number and percentage of shares of Common Stock deemed beneficially owned by the Reporting Persons (based on 36,031,964 shares of Common Stock outstanding as of May 9, 2023, and 60 days out for vesting of options,), are as follows:
(a) | Common Shares deemed beneficially owned: | Percent of class of Common Shares: |
(i) Mr. Wolf: | 10.5% | |
(ii) Orion: | *% | |
(iii) Seed-One: | *% | |
(iv) Elusys Holdings | *% |
*less than 1%
(b) Number of Common Shares as to which Mr. Wolf has:
(i) | Sole power to vote or to direct the vote: 4,104,922 | |
(ii) | Shared power to vote or to direct the vote: 21,256 | |
(iii) | Sole power to dispose or to direct the disposition of: 4,104,922 | |
(iv) | Shared power to vote or to direct the disposition of: 21,256 |
Number of Common Shares as to which Orion has:
(i) | Sole power to vote or to direct the vote: 0 | |
(ii) | Shared power to vote or to direct the vote: 11,025 | |
(iii) | Sole power to dispose or to direct the disposition of: 0 | |
(iv) | Shared power to vote or to direct the disposition of: 11,025 |
Number of Common Shares as to which Seed-One has:
(i) | Sole power to vote or to direct the vote: 0 | |
(ii) | Shared power to vote or to direct the vote: 10,231 | |
(iii) | Sole power to dispose or to direct the disposition of: 0 | |
(iv) | Shared power to vote or to direct the disposition of: 10,231 |
Number of Common Shares as to which Elusys Holdings has:
(i) | Sole power to vote or to direct the vote: 0 | |
(ii) | Shared power to vote or to direct the vote: 0 | |
(iii) | Sole power to dispose or to direct the disposition of: 0 | |
(iv) | Shared power to vote or to direct the disposition of: 0 |
(c) None of the Reporting Persons effected any transactions in Common Stock during the 60 days prior to the date hereof.
(d) Not applicable.
(e) Not applicable.
Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. |
The information in Items 2 and 4 of this Schedule 13D is incorporated herein by reference.
CUSIP No. 42237K 409 | 13D | Page 8 of 9 Pages |
Item 7. | Material to Be Filed as Exhibits. |
Item 7 is hereby amended and supplemented by adding the following:
Exhibit 1: | Joint Filing Agreement, dated May 13, 2024 |
Exhibit 2: | Form of Warrant (incorporated by reference to Exhibit 4.21 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 13, 2024). |
CUSIP No. 42237K 409 | 13D | Page 9 of 9 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: May 13, 2024 | ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
ORION HOLDINGS V, LLC
| ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Managing Member |
SEED-ONE HOLDINGS VI, LLC | ||
| ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Managing Member |
ELUSYS HOLDINGS INC.
| ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Chief Executive Officer |
Exhibit 1
JOINT FILING AGREEMENT
This JOINT FILING AGREEMENT, is dated as of May 13, 2024, and is by and among Jeffrey Wolf, Orion Holdings V, LLC, a Delaware limited liability company (“Orion”), Seed-One Holdings VI, LLC, a Delaware limited liability company (“Seed-One”), and Elusys Holdings Inc., a Delaware corporation (“Elusys Holdings,” and collectively with Mr. Wolf, Orion, and Seed-One, the “Reporting Persons”).
WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties hereto desire to satisfy any filing obligation under Section 13(d) of the Exchange Act by a single joint filing;
NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Reporting Persons hereby agree and represent as follows:
1. Amendment No. 10 to Schedule 13D with respect to the Common Stock, par value $0.0002 per share, of Scorpius Biosciences, Inc. (to which this Joint Filing Agreement is an exhibit) is filed on behalf of each of the Reporting Persons.
2. Each of the Reporting Persons is responsible for the timely filing of Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such Person contained therein, provided that each such Person is not responsible for the completeness or accuracy of the information concerning any of the other Reporting Persons, unless such Person knows or has reason to believe that such information is inaccurate.
IN WITNESS WHEREOF, the undersigned have caused this Joint Filing Agreement to be duly executed and delivered as of the date first above written.
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
ORION HOLDINGS V, LLC
| ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Managing Member |
SEED-ONE HOLDINGS VI, LLC | ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Managing Member |
ELUSYS HOLDINGS INC.
| ||
By: | /s/ Jeffrey Wolf | |
Name: Jeffrey Wolf | ||
Title: Chief Executive Officer |